BeOne Medicines makes prescription medicines, including BRUKINSA and TEVIMBRA, and sells them in several countries. ONC reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell). In the past 30 days there were 3 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 8 | RBC Capital | Target raised | Buy | |
| Oct 7 | Truist Securities | Target raised | Buy | |
| Oct 1 | JP Morgan | Target raised | Buy | |
| Sep 10 | Barclays | Maintained | Buy | |
| Aug 6 | TD Cowen | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in ONC in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ONC is in one of them and how their past ONC trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ONC in an article yet. Here's the latest on the wider market.
About BeOne Medicines
BeOne Medicines makes prescription medicines, including BRUKINSA and TEVIMBRA, and sells them in markets including the U.S., China and Europe. It is headquartered in Basel, Switzerland. Its customers include patients, hospitals and government and private health insurance payors, which set the coverage and reimbursement terms that affect how its medicines are sold.
- Headquarters
- Basel